Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated in Q2 2026 Cash, cash equivalents, and investments of $61.0 million as of March 31, 2026; runway into second...
-
Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026 Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus...
-
New York, USA, March 09, 2026 (GLOBE NEWSWIRE) -- Herpes Zoster Market Poised for Robust Growth During the Forecast Period (2026–2036) Driven by Rising Incidence and Vaccine Adoption | DelveInsight ...
-
Dublin, March 09, 2026 (GLOBE NEWSWIRE) -- The "Heplisav-B Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering....
-
Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...
-
Sanofi finalise l’acquisition de Dynavax Paris, le 10 février 2026. Sanofi a annoncé aujourd’hui avoir finalisé l’acquisition de Dynavax Technologies Corporation (Dynavax). L’acquisition comprend le...
-
Ottawa, Jan. 20, 2026 (GLOBE NEWSWIRE) -- The global biotechnology market size is calculated at USD 2.45 trillion in 2025, grew to USD 2.79 trillion in 2026, and is projected to reach around USD...
-
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for...
-
Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline Paris, December 24, 2025. Sanofi announced today that it has entered into an...
-
Sanofi va acquérir Dynavax et ajouter un vaccin commercialisé contre l’hépatite B pour adultes et un candidat vaccin de phase 1⁄2 contre le zona au pipeline Paris, le 24 décembre 2025. Sanofi a...